A 2026 BMJ study found GLP-1 drugs like Ozempic carry a 37–68% higher alopecia risk vs. other diabetes medications. The post ...

It started as a routine phonics lesson in the 1st grade Bronx classroom I was observing to study how students learn to read.

The Delhi High Court has observed that students who spend “hours and months” preparing for admission to premier institutions ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds ...

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and ...

The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes ...

Discusses Update and Growth Initiatives for Araxa Niobium and Rare Earths Project in Brazil July 21, 2026 9:00 ...

A new study looking at nearly 877,000 people with type 2 diabetes found that patients who used GLP-1 medications had a higher risk of developing issues with their sense of smell and taste compared to ...

Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28’s development path directly into a pivotal Phase 3 studyWith the vast majority of PMD patients having no ...

Emergency physicians say the growing popularity of high-speed electric bikes is fueling a rise in serious pediatric injuries.

A mom who returned to university in her 60s has graduated alongside her daughter after years of late-night study sessions ...

ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month 12Results from ACTiVION-I, the second Phase 3 trial of ...